Related references
Note: Only part of the references are listed.Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
Klaus P. Hoeflich et al.
CANCER RESEARCH (2009)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Michael A. Davies et al.
CLINICAL CANCER RESEARCH (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Stephen D. Barrett et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Dual-specificity MAP kinase phosphatases (MKPs) and cancer
Stephen M. Keyse
CANCER AND METASTASIS REVIEWS (2008)
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression
Keiran S. M. Smalley et al.
CANCER RESEARCH (2008)
Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
Christine A. Pratilas et al.
CANCER RESEARCH (2008)
BRAF V600E disrupts AZD6244-Induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins
Bret B. Friday et al.
CANCER RESEARCH (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
A negative feedback signaling network underlies oncogene-induced senescence
Stephanie Courtois-Cox et al.
CANCER CELL (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Rote of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1
E O'Neill et al.
SCIENCE (2004)
Modulation of signalling by sprouty: A developing story
HJ Kim et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism
J Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
